Abraxis Oncology
 
Bookmark Send to a Colleague
Investor Relations
Home > Investor Relations

Investor Relations

We are in the process of updating this section. Please check back for updates.

Investor and Media Relations Contact:
Daniel Saks
Tel: 310.405.7417
Email: dsaks@abraxisbio.com
Latest News
  • 04/15/08 - Abraxis BioScience Presents New Preclinical Data Demonstrating Eradication of Large Orthotopic Breast Tumors and Metastasis with Combined nab-Paclitaxel (ABRAXANE(R)) and Bevacizumab (Avastin(R)) Therapy
  • 04/09/08 - Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in Korea
  • 04/04/07 - Abraxis BioScience Acquires Shimoda Biotech and Platco Technologies
Compliance Declaration Investor Relations Site Map Terms of Use Privacy Policy Glossary Comprehensive Bibliography

Abraxis Oncology is a division of Abraxis BioScience, LLC. AO 997/268353 August 2008
All Abraxis BioScience, LLC corporate names (eg, ABRAXIS, ABRAXIS ONCOLOGY, ABRAXIS BIOSCIENCE, and their logos), names of services, and names of products (eg, ABRAXANE® and the ABRAXANE logo) referred to herein are trade names, service marks and/or trademarks that are owned by or licensed to Abraxis BioScience, its divisions, or its affiliates, unless otherwise noted.